A. Preston

1.7k total citations
18 papers, 1.2k citations indexed

About

A. Preston is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Genetics. According to data from OpenAlex, A. Preston has authored 18 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 7 papers in Pulmonary and Respiratory Medicine and 6 papers in Genetics. Recurrent topics in A. Preston's work include HER2/EGFR in Cancer Research (7 papers), Chronic Lymphocytic Leukemia Research (6 papers) and Colorectal Cancer Treatments and Studies (6 papers). A. Preston is often cited by papers focused on HER2/EGFR in Cancer Research (7 papers), Chronic Lymphocytic Leukemia Research (6 papers) and Colorectal Cancer Treatments and Studies (6 papers). A. Preston collaborates with scholars based in United States, United Kingdom and Netherlands. A. Preston's co-authors include María Koehler, Julie Byrne, Erica Rappold, Michael S. Ewer, Edith A. Perez, Élisabeth Quoix, Graham Ross, Joachim von Pawel, Zsolt Pápai and John R. Eckardt and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and Mayo Clinic Proceedings.

In The Last Decade

A. Preston

17 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
A. Preston United States 11 932 291 278 271 221 18 1.2k
Jessica Read United Kingdom 9 733 0.8× 428 1.5× 56 0.2× 247 0.9× 514 2.3× 11 1.6k
A. Fornasiero Italy 17 700 0.8× 141 0.5× 60 0.2× 390 1.4× 323 1.5× 43 1.6k
Jennifer Arrondeau France 20 838 0.9× 317 1.1× 46 0.2× 96 0.4× 522 2.4× 74 1.3k
Dale R. Shepard United States 17 478 0.5× 419 1.4× 44 0.2× 60 0.2× 470 2.1× 75 1.2k
Rita Lionetto Italy 20 962 1.0× 133 0.5× 185 0.7× 60 0.2× 320 1.4× 53 1.4k
Vito Spataro Switzerland 13 482 0.5× 370 1.3× 208 0.7× 59 0.2× 156 0.7× 26 1.0k
Harry F. Bisel United States 18 676 0.7× 222 0.8× 192 0.7× 74 0.3× 320 1.4× 38 1.3k
Philippe Montcuquet France 16 581 0.6× 247 0.8× 100 0.4× 38 0.1× 332 1.5× 38 919
Ali Manouchehri United States 7 978 1.0× 197 0.7× 415 1.5× 87 0.3× 287 1.3× 13 1.5k

Countries citing papers authored by A. Preston

Since Specialization
Citations

This map shows the geographic impact of A. Preston's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A. Preston with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A. Preston more than expected).

Fields of papers citing papers by A. Preston

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by A. Preston. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A. Preston. The network helps show where A. Preston may publish in the future.

Co-authorship network of co-authors of A. Preston

This figure shows the co-authorship network connecting the top 25 collaborators of A. Preston. A scholar is included among the top collaborators of A. Preston based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with A. Preston. A. Preston is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Preston, A., et al.. (2012). CT pulmonary angiography in elderly patients: Outcomes in patients aged >85 years. Clinical Radiology. 68(5). 449–454. 3 indexed citations
2.
Spraggs, Colin F., Linda P. Briley, Nan Bing, et al.. (2011). HLA-DQA1 * 02:01 Is a Major Risk Factor for Lapatinib-Induced Hepatotoxicity in Women With Advanced Breast Cancer. Journal of Clinical Oncology. 29(6). 667–673. 199 indexed citations
3.
Briley, Linda P., Mathias Chiano, Karen S. King, et al.. (2011). Pharmacogenetic investigation of lapatinib-associated diarrhea in metastatic breast cancer clinical trials.. Journal of Clinical Oncology. 29(15_suppl). 552–552. 1 indexed citations
4.
Kaiser, Lee D., Allen S. Melemed, A. Preston, et al.. (2010). Optimizing Collection of Adverse Event Data in Cancer Clinical Trials Supporting Supplemental Indications. Journal of Clinical Oncology. 28(34). 5046–5053. 13 indexed citations
5.
Spraggs, Colin F., Linda P. Briley, Nan Bing, et al.. (2010). Relationship of HLA-DQA1*0201 and lapatinib-induced hepatotoxicity in women with advanced breast cancer.. Journal of Clinical Oncology. 28(15_suppl). 3100–3100. 1 indexed citations
6.
Capri, Giuseppe, José Chang, Pierfranco Conté, et al.. (2009). An open-label expanded access study of lapatinib and capecitabine in patients with HER2-overexpressing locally advanced or metastatic breast cancer. Annals of Oncology. 21(3). 474–480. 64 indexed citations
7.
Perez, Edith A., María Koehler, Julie Byrne, et al.. (2008). Cardiac Safety of Lapatinib: Pooled Analysis of 3689 Patients Enrolled in Clinical Trials. Mayo Clinic Proceedings. 83(6). 679–686. 238 indexed citations
8.
Lacouture, Mario E., María Koehler, Robert Sweetman, et al.. (2008). Analysis of dermatologic events in patients with cancer treated with lapatinib. Breast Cancer Research and Treatment. 114(3). 485–493. 73 indexed citations
9.
Crown, John, H. A. Burris, Frances M. Boyle, et al.. (2008). Pooled analysis of diarrhea events in patients with cancer treated with lapatinib. Breast Cancer Research and Treatment. 112(2). 317–325. 75 indexed citations
10.
Crown, John, H. A. Burris, Frances M. Boyle, et al.. (2008). Pooled analysis of diarrhea events in patients with cancer treated with lapatinib. Breast Cancer Research and Treatment. 113(2). 409–410. 2 indexed citations
11.
Perez, Edith A., María Koehler, Julie Byrne, et al.. (2008). Cardiac Safety of Lapatinib: Pooled Analysis of 3689 Patients Enrolled in Clinical Trials. Mayo Clinic Proceedings. 83(6). 679–686. 217 indexed citations
12.
Eckardt, John R., Joachim von Pawel, Jean-Louis Pujol, et al.. (2007). Phase III Study of Oral Compared With Intravenous Topotecan As Second-Line Therapy in Small-Cell Lung Cancer. Journal of Clinical Oncology. 25(15). 2086–2092. 274 indexed citations
13.
Storniolo, A. M., María Koehler, A. Preston, et al.. (2007). Cardiac safety in patients (pts) with metastatic breast cancer (MBC) treated with lapatinib (L) and trastuzumab (TRA). Journal of Clinical Oncology. 25(18_suppl). 514–514. 10 indexed citations
14.
Burris, H.A., Mario E. Lacouture, B. Newstat, et al.. (2007). 2112 POSTER Pooled analysis of skin and diarrhea events in cancer patients treated with lapatinib. European Journal of Cancer Supplements. 5(4). 217–217. 1 indexed citations
15.
Sweetman, Robert, et al.. (2007). Skin events (SE) among 1,126 patients (Pts) treated with lapatinib (L), an oral dual ErbB1/2 tyrosine kinase inhibitor (TKI). Journal of Clinical Oncology. 25(18_suppl). 9102–9102. 4 indexed citations
16.
17.
18.
Preston, A., et al.. (1999). Screening for urinary tract infections in a gynaecological setting: validity and cost-effectiveness of reagent strips.. PubMed. 56(4). 253–7. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jessica Read Breakdown of academic impact, for papers by A. Fornasiero Breakdown of academic impact, for papers by Jennifer Arrondeau Breakdown of academic impact, for papers by Dale R. Shepard Breakdown of academic impact, for papers by Rita Lionetto Breakdown of academic impact, for papers by Vito Spataro Breakdown of academic impact, for papers by Harry F. Bisel Breakdown of academic impact, for papers by Philippe Montcuquet Breakdown of academic impact, for papers by Ali Manouchehri
Rankless by CCL
2026